BioCentury | Aug 18, 2017
Emerging Company Profile

Teasing out Th1

...incurring the immunosuppressive effects caused by Th2 cell activation. Like most cancer vaccines in development, EpiThany's...
...in tumor cells than in healthy cells. However, CEO Bill Watt told BioCentury the antigens EpiThany...
..."If your antigen construct contains a Th2 epitope, it will undermine the vaccine's Th1 immunogenicity." EpiThany...
BioCentury | May 12, 2017
Company News

EpiThany to conduct Phase II breast cancer trial of cancer vaccine EP-101 plus Bavencio

...carcinoma and to treat Merkel cell carcinoma (MCC). The companies declined to disclose financial terms. EpiThany...
...Seattle, Wash. Merck KGaA (Xetra:MRK), Darmstadt, Germany Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cancer Julian Zhu avelumab Bavencio MSB0010718C PF-06834635 EpiThany...
Items per page:
1 - 2 of 2